Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11C-LSN3172176
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
11C-LSN3172176 (also known as 11C-EMO) is a carbon-11 radiolabeled positron emission tomography (PET) imaging tracer developed for the in vivo quantification of muscarinic acetylcholine M1 receptors (M1 mAChR) in the brain. The parent compound, LSN3172176, is a potent, selective, bitopic partial agonist of the M1 receptor originally developed by Eli Lilly. 11C-LSN3172176 exhibits high brain uptake, favorable reversible kinetics, and high specific binding in M1-rich regions such as the striatum, hippocampus, and cortex. It is utilized as a diagnostic tool in clinical research to evaluate M1 receptor availability and target engagement in neuropsychiatric and neurodegenerative disorders, including schizophrenia and cocaine use disorder.
- Other names
- [11C]EMO[11C]LSN317217611C-EMOC-LSN3172176C-LSN-3172176C-LSN 3172176carbon-11 LSN3172176carbon11 LSN3172176carbon 11 LSN3172176ethyl 4-(6-(methyl-11C)-2-oxoindolin-1-yl)-[1,4'-bipiperidine]-1'-carboxylate
02
Targets
M1 (Muscarinic acetylcholine receptor M1)
Beyond the preview
Go deeper on 11C-LSN3172176.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 11C-LSN3172176.